The company is collaborating with two UK institutes to assess whether its Signatera ctDNA technology can detect disease recurrence in women treated for breast cancer.
Areas of concern are the recruitment of talented scientists, as well as retaining access to EU funding, European research collaborations, and clinical trials.
The researchers will sequence the genomes and transcriptomes of 250 breast cancer patients in the first phase, returning information from 16 actionable genes.
Inivata plans to use the new funds to accelerate clinical studies to validate its liquid biopsy technology platform and commercialize its first products.
The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.
Women who post YouTube science videos get more critical comments and more comments about their appearance than male video hosts, the New York Times reports.
